Bosutinib treatment for Philadelphia chromosome-positive leukemias.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Future Oncol

Title: Future oncology (London, England)

Publisher: Future Medicine Ltd

ISSN (Electronic): 1744-8301

ISSN (Print): 1479-6694

Publication date (Electronic): Feb 2014

Volume: 10

Issue: 2

Affiliations

[1 ] Division of Hematology, Department of Hematology & Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA.

Article

DOI: 10.2217/fon.13.268

PubMed ID: 24490604

SO-VID: 60d6babd-18b8-4bc3-a8f9-654960806b20

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by